International Center of Excellence for oncology biomarker and inflammation translational services created
San Diego, Calif – May 9, 2019 – Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular, and metabolic disease research, today announced the opening of a new facility in San Diego, CA. The new site will become CrownBio’s International Center of Excellence for oncology biomarker and inflammation services.
CrownBio’s presence in San Diego, CA has grown from 17 employees in 2015 to more than 70 today, with additional hiring expected. The custom-designed 32,000 sq. ft. facility provides the additional capacity required to support the growth CrownBio forecasts in its oncology biomarker and inflammation service portfolios. As part of the expansion, significant investment was also made in the latest flow cytometry, radiation and imaging technologies.
In the newly created Center of Excellence, CrownBio will enhance its current translational platforms by expanding its existing service portfolio, as well as develop an additional new suite of oncology and inflammation platforms.
The fully-operational facility is designed to ensure a streamlined workflow to optimize study efficiency. Featuring a state-of-the-art ABSL-2 vivarium and laboratory housing an infectious suite and quarantine facilities, the new site hosts significant laboratory space dedicated to storing cryo-preserved cells and tissue, including the world’s largest commercially available collection of patient-derived xenograft (PDX) models.
“The establishment of our International Center of Excellence in San Diego is both an indicator of our continued growth and a commitment to our global and domestic customers,” said CrownBio COO Yangzhou Wang. “The expansion allows us to add to our talented and diverse workforce, which will in turn support the development of novel cancer therapies globally.”
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Contact details
-
- Louise Stenson
-
Crown Bioscience Company Inquiries
Communications Manager - louise.stenson@crownbio.com
Copy link
https://news.jsrlifesciences.com/212684-crown-bioscience-announces-san-diego-ca-site-expansionRelated topics
Related news
Crown Bioscience Appoints John Gu as Chief Executive Officer
Crown Bioscience appoints John Gu as CEO, leveraging his expertise in AI-driven drug discovery to advance biotechnological innovation and global health.
Crown Bioscience Completes Merger with Indivumed Services
Crown Bioscience completes Indivumed Services merger, offering enhanced drug development solutions globally and retiring the Indivumed brand.
Crown Bioscience Germany GmbH Achieves Continued CAP 15189:2022 Accreditation
Crown Bioscience's Hamburg site secures continued CAP ISO 15189:2022 accreditation, showcasing its commitment to quality in laboratory services.
Crown Bioscience Wins 2024 Fierce CRO Award for Excellence in Client Service and Partnership
Crown Bioscience wins 2024 Fierce CRO Award for excellence in client service, underscoring its commitment to innovative drug development partnerships.
Crown Bioscience Wins BioTech Breakthrough Award for Drug Development Innovation
Crown Bioscience's OrganoidXplore receives BioTech Award, revolutionizing oncology with advanced preclinical screening.